| Combigan (brimonidine tartrate/timolol maleate) / AbbVie |
NCT00822081: Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 4 | 140 | Canada | brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination, Combigan., dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination, Cosopt., brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy., dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy., Cosopt | Bp Consulting, Inc, Allergan | Open-Angle Glaucoma, Ocular Hypertension | 04/06 | 04/06 | | |
NCT00822055: Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 4 | 140 | Canada | brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination, Combigan®, dorzolamide hcl 2%/timolol maleate 0.5% fixed combination, Cosopt®, brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy, dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy | Allergan | Open-Angle Glaucoma, Ocular Hypertension | 11/06 | 11/06 | | |
NCT00442312: Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy |
|
|
| Unknown status | 4 | 43 | RoW | Combigan Ophthalmic Solutiom | Genovate Biotechnology Co., Ltd.,, Allergan Medical | Glaucoma | | 11/06 | | |
NCT00972257: 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination |
|
|
| Completed | 4 | 64 | Europe | treatment with dorzolamide/timolol, treatment with brimonidine/timolol | Aristotle University Of Thessaloniki | Glaucoma | 09/09 | 09/09 | | |
NCT00735449: Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects |
|
|
| Completed | 4 | 204 | Canada, US | Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%, Combigan®, timolol maleate 0.5%, Timpoptic®, Timoptol®, latanoprost 0.005%, Xalatan® | Allergan | Glaucoma, Ocular Hypertension | 12/09 | 12/09 | | |
NCT00811850: Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow |
|
|
| Completed | 4 | 15 | US | fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, Combigan®, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution, Cosopt® | Allergan | Glaucoma | 12/09 | 12/09 | | |
NCT00811564: An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects |
|
|
| Completed | 4 | 148 | US | fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, Combigan™, latanoprost 0.005%, Xalatan™ | Allergan | Glaucoma, Ocular Hypertension | 01/10 | 01/10 | | |
NCT00981786: 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol |
|
|
| Completed | 4 | 51 | NA | Brimonidine/timolol fixed combination drops added to travoprost, Combigan, Brinzolamide/timolol fixed combination drops added to travoprost, Azarga | Aristotle University Of Thessaloniki, Alcon Research | Glaucoma | 09/10 | 12/10 | | |
NCT01170884: Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan® |
|
|
| Completed | 4 | 121 | US | fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, COMBIGAN®, LUMIGAN®, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops, Gen Teal® Mild | Allergan | Glaucoma, Ocular Hypertension | 09/10 | 09/10 | | |
NCT01446497: Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma |
|
|
| Unknown status | 4 | 22 | RoW | Brimonidine/Timolol mixed combination, Combigan, Timolol, Timoptic XE | Seoul National University Hospital | Normal Tension Glaucoma | 08/11 | 08/12 | | |
| Completed | 4 | 35 | US | Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension, AZARGA™, Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution, COMBIGAN® | Alcon Research | Glaucoma | 01/12 | 01/12 | | |
NCT01151904: Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients |
|
|
| Terminated | 4 | 17 | RoW | brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution, COMBIGAN®, latanoprost | Allergan | Glaucoma, Angle-Closure | 02/12 | 02/12 | | |
NCT01514734: Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil |
|
|
| Terminated | 4 | 9 | RoW | Brinzolamide/timolol maleate fixed combination, AZARGA® | Alcon Research | Glaucoma | 08/12 | 08/12 | | |
NCT01518244: Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America |
|
|
| Completed | 4 | 50 | RoW | Brinzolamide/timolol maleate fixed combination, AZARGA® | Alcon Research | Glaucoma | 02/13 | 02/13 | | |
NCT01415401: Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada |
|
|
| Completed | 4 | 57 | Canada | Brinzolamide 1% / timolol 0.5% maleate fixed combination, AZARGA® | Alcon Research | Glaucoma, Ocular Hypertension, Open-angle Glaucoma | 06/13 | 06/13 | | |
2013-001634-17: LONG-TERM 24-HOUR INTRAOCULAR PRESSURE CONTROL AND PROGRESSION RATE OBTAINED WITH THE ASSOCIATION OF COMBIGAN IN THE MORNING AND GANFORT IN THE EVENING COMPARED WITH LATANOPROST IN HIGH RISK OPEN-ANGLE GLAUCOMA. Controllo della pressione intraoculare nelle 24 ore e velocità di progressione della malattia ottenuto con la somministrazione di Combigan al mattino e Ganfort la sera rispetto alla somministrazione di Latanoprost la sera nei pazienti con nuova diagnosi di glaucoma ad angolo aperto o Glaucoma esfoliativo ad alto rischio di progressione. |
|
|
| Completed | 4 | 60 | Europe | COMBIGAN, GANFORT, LATANOPROST, LATANOPROST, Eye drops, Ear drops, COMBIGAN COLLIRIO 5 ML, GANFORT 0,3 mg/ml + 5 mg/ml, LATANOPROST | AZIENDA OSPEDALIERA S. PAOLO, Allergan Pharmaceuticals | Patients with glaucoma open angle or glaucoma exfoliative with high risknewly diagnosed and untreated. Pazienti con glaucoma angolo aperto o glauco esfoliativo ad alto rischio con nuova diagnosi e non trattati., Patients with glaucoma open angle or glaucoma exfoliative with high risknewly diagnosed and untreated. Pazienti con glaucoma angolo aperto o glauco esfoliativo ad alto rischio con nuova diagnosi e non trattati., Diseases [C] - Eye Diseases [C11] | | | | |
NCT02167035: Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) |
|
|
| Completed | 4 | 43 | US | Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID) | Cornerstone Health Care, PA, Allergan | Glaucoma, Ocular Hypertension | 03/18 | 03/18 | | |
NCT02863705: Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) |
|
|
| Completed | 4 | 118 | RoW | brimonidine tartrate/timolol malate Ophthalmic Solution, bimatoprost ophthalmic solution 0.01% | Allergan | Glaucoma, Open-Angle, Normal Tension Glaucoma | 07/18 | 07/18 | | |
BCT, NCT06078592: Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive |
|
|
| Completed | 4 | 60 | RoW | BRIDIN-plus Eye drops, Brimonidine tartrate 2.0mg, Timolol maleate 6.8mg(without preservative), Combigan Eye drops, Brimonidine tartrate 2.0mg, Timolol maleate 6.8mg(with preservative) | CHA University, Hanlim Pharm. Co., Ltd. | Glaucoma, Ocular Hypertensive | 12/22 | 12/22 | | |
